AZNWatch

AstraZeneca

$172.48

Community outlook

Bearish44%

Questions Discussion Earnings Data & analysis

Next report

Wed, 4 Nov 2026

in 98 days

EPS estimate

$2.74

Wall Street consensus

Revenue estimate

$16.6B

Wall Street consensus

Expected swing

±17.0%

±1σ by report day, from realized volatility

Also reporting that week:AMD PFE PLTR SHOP SMCI SPOT UBER HOOD

EPS outlook

Odds turned into a number: where the print lands if AZN's usual surprise repeats — and what the crowd's beat odds imply on the same scale.

Street estimate

$•.••

the bar to clear

If history repeats

$•.••

•• of •• quarters beat

Crowd implies

—

needs more forecasts on the beat question

Typical range for the print: $•.•• – $•.••±1σ of past surprises
Beat odds implied by the record: ••%ceiling on •• quarters

A beat probability is a statement about where the print sits relative to the estimate. Scaled by how far recent quarters landed from the Street, it becomes a dollar figure. Not a forecast of the stock — companies fall on beats.

The crowd's read

Live odds from the community — tap through to make your own call.

Will AstraZeneca be higher in 6 months than today?

Nearest crowd call that settles after the report · 6 forecasting

45%

Forecast

The Street's stance

Analyst consensus — and whether it has been improving or souring into the print.

Buy

35 analysts · 29 buy · 4 hold · 2 sell

steady over the last 3 months

Estimate track record

Reported EPS against the Street's estimate, most recent first — the same feed our earnings questions settle on.

Beat rate

2 of 4

quarters beat the estimate

Avg surprise

+0.7%

vs EPS estimate

Quarter	Estimate	Actual	Surprise	Result
Jun 2026	$2.55	$2.63	+3.1%	BEAT
Mar 2026	$2.59	$2.58	-0.5%	MISS
Dec 2025

Fundamentals snapshot

Trailing-twelve-month figures for context around the print.

Market cap

$199.9B

EPS (TTM)

$6.69

P/E (TTM)

25.4

price ÷ trailing earnings

Revenue growth

+8.6%

TTM vs a year ago

Gross margin

81.3%

of revenue kept after costs

Net margin

17.0%

of revenue kept as profit

52-week range

$10,744 – $15,730

now $172.48

Beta

1.38

moves harder than the market

Dividend yield

Estimates and reported figures via Finnhub; crowd odds are AstraZeneca forecasts on Probs. Information, not investment advice.